» Articles » PMID: 744105

Interaction of Gastric Inhibitory Polypeptide, Glucose, and Arginine on Insulin and Glucagon Secretion from the Perfused Rat Pancreas

Overview
Journal Endocrinology
Specialty Endocrinology
Date 1978 Aug 1
PMID 744105
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric inhibitory polypeptide (GIP) produced an increase in immunoreactive insulin (IRI) and immunoreactive glucagon (IRG) release from the isolated perfused rat pancreas. The magnitude of both effects was shown to be dependent on the prevailing glucose concentration. GIP stimulated IRG release at glucose concentrations less than 5.5 mM and IRI release at glucose levels greater than 5.5 mM. Arginine"stimulated IRG secretion in the presence of low glucose (2.7 mM) was potentiated by GIP. In contrast, GIP augmented arginine-stimulated insulin release only in the presence of arginine concentrations of (less than 20 mM, producing no further increase over a maximal arginine stimulus. The glucagonotropic effect of GIP in the presence of arginine was found to be suppressed by glucose, with the opposite effect observed with insulin release. It was concluded that the endocrine pancreatic action of GIP depends to a great degree on existing levels of modulating nutrients in the blood.

Citing Articles

Impaired Incretin Homeostasis in Nondiabetic Moderate-to-Severe CKD.

Ahmadi A, Gamboa J, Norman J, Enkhmaa B, Tucker M, Bennett B Clin J Am Soc Nephrol. 2024; 20(1):12-22.

PMID: 39480994 PMC: 11737449. DOI: 10.2215/CJN.0000000000000566.


Evaluating glucose-dependent insulinotropic polypeptide and glucagon as key regulators of insulin secretion in the pancreatic islet.

Lewandowski S, El K, Campbell J Am J Physiol Endocrinol Metab. 2024; 327(1):E103-E110.

PMID: 38775725 PMC: 11390117. DOI: 10.1152/ajpendo.00360.2023.


DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus.

Shao Y, Chen Y, Zhu M, Liu Y, Fang C, Wang M Diabetes Metab Syndr Obes. 2024; 17:1563-1573.

PMID: 38601038 PMC: 11005929. DOI: 10.2147/DMSO.S457830.


The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.

Jakubowska A, le Roux C, Viljoen A Endocrinol Metab (Seoul). 2024; 39(1):12-22.

PMID: 38356208 PMC: 10901658. DOI: 10.3803/EnM.2024.1942.


Impaired incretin homeostasis in non-diabetic moderate-severe CKD.

Ahmadi A, Gamboa J, Norman J, Enkhmaa B, Tucker M, Bennett B medRxiv. 2024; .

PMID: 38196612 PMC: 10775324. DOI: 10.1101/2023.12.15.23300050.